Literature DB >> 20442353

Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative.

Benoit Cossette1, Marie-Eve Pelletier, Nathalie Carrier, Martin Turgeon, Christian Leclair, Pierre Charron, Donald Echenberg, Tania Fayad, Paul Farand.   

Abstract

BACKGROUND: Bleeding associated with the use of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) can be a serious complication of health-care management and should be the focus of quality improvement initiatives by institutions.
OBJECTIVE: To measure the incidence of bleeding with UFH and LMWH and evaluate associated risk factors.
METHODS: An observational cohort study was conducted at a secondary and tertiary care hospital in Canada. All adults receiving therapeutic doses of UFH or LMWH between April 2006 and March 2007, with the exception of cardiac surgery patients, were included. Bleeding episodes were classified per the GUSTO scale.
RESULTS: Of 3066 hospitalizations, the incidence of moderate or severe bleeding was 3.5%. Advanced age (OR 1.02, 95% CI 1.01 to 1.04; p < 0.001), female sex (OR 1.80, 95% CI 1.21 to 2.66; p = 0.003), UFH instead of LMWH (OR 4.72, 95% CI 2.17 to 10.30; p < 0.001), creatinine clearance (CrCl) (OR 0.89, 95% CI 0.84 to 0.95; p < 0.001, for a difference of 10 mL/min in CrCl), and supratherapeutic activated partial thromboplastin time (aPTT) (OR 3.88, 95% CI 2.25 to 6.69; p < 0.001 for >180 vs <90 seconds) were associated with a higher risk of bleeding in univariate analysis. In a multivariate model without aPTT, CrCl (OR 0.90, 95% CI 0.85 to 0.96; p < 0.001, for a difference of 10 mL/min in CrCl) and UFH (OR 2.35, 95% CI 1.11 to 4.98; p = 0.005) were significant predictors of bleeding. Among the bleeding episodes, 31% were in a postoperative context and 15% were following a puncture.
CONCLUSIONS: Our findings show that CrCl and aPTT values, as well as the type of heparin used, are significant predictors of bleeding in patients receiving UFH or LMWH and that dosages should be adjusted to patient weight. The reason for all supratherapeutic aPTT levels should be sought and corrective measures taken immediately.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442353     DOI: 10.1345/aph.1M615

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  15 in total

Review 1.  Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures.

Authors:  Ali Faramarzalian; Keith B Armitage; Baljendra Kapoor; Sanjeeva P Kalva
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

2.  Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding.

Authors:  Guoping Chen; Wangyin Shi; Xu He; Wensheng Lou; Liang Chen; Jianping Gu
Journal:  Exp Ther Med       Date:  2017-01-04       Impact factor: 2.447

Review 3.  Surgical embolectomy for acute massive pulmonary embolism: state of the art.

Authors:  Alessandra Iaccarino; Giacomo Frati; Leonardo Schirone; Wael Saade; Elio Iovine; Mizar D'Abramo; Antonio De Bellis; Sebastiano Sciarretta; Ernesto Greco
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy.

Authors:  Cliodhna Browne; Niall F Davis; William J Nolan; Eoin D MacCraith; Gerald M Lennon; David W Mulvin; David J Galvin; David M Quinlan
Journal:  Curr Urol       Date:  2017-07-30

Review 5.  Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.

Authors:  Kang-Ling Wang; Pao-Hsien Chu; Cheng-Han Lee; Pei-Ying Pai; Pao-Yen Lin; Kou-Gi Shyu; Wei-Tien Chang; Kuan-Ming Chiu; Chien-Lung Huang; Chung-Yi Lee; Yen-Hung Lin; Chun-Chieh Wang; Hsueh-Wei Yen; Wei-Hsian Yin; Hung-I Yeh; Chern-En Chiang; Shing-Jong Lin; San-Jou Yeh
Journal:  Acta Cardiol Sin       Date:  2016-01       Impact factor: 2.672

6.  Evaluation of initial heparin infusion rates for a high-dose protocol.

Authors:  Adam Smith; Eileen M Stock; Nathan Fewel; Michael Rose; Carrie L Griffiths
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

7.  [Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].

Authors:  P W Radke; M Möckel
Journal:  Herz       Date:  2018-02       Impact factor: 1.443

8.  Pulmonary Embolism and Unfractionated Heparin: Time to End the Roller Coaster Ride.

Authors:  Aaron W Aday; Joshua A Beckman
Journal:  Acad Emerg Med       Date:  2019-11-07       Impact factor: 3.451

9.  Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.

Authors:  Malaika D Argade; Akul Y Mehta; Aurijit Sarkar; Umesh R Desai
Journal:  J Med Chem       Date:  2014-04-07       Impact factor: 7.446

10.  Improved recovery from limb ischaemia by delivery of an affinity-isolated heparan sulphate.

Authors:  Selina Poon; Xiaohua Lu; Raymond A A Smith; Pei Ho; Kishore Bhakoo; Victor Nurcombe; Simon M Cool
Journal:  Angiogenesis       Date:  2018-05-18       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.